KR20220063029A - Composition for preventing or treating cachexia comprising medicinal herb complex extract - Google Patents
Composition for preventing or treating cachexia comprising medicinal herb complex extract Download PDFInfo
- Publication number
- KR20220063029A KR20220063029A KR1020200148877A KR20200148877A KR20220063029A KR 20220063029 A KR20220063029 A KR 20220063029A KR 1020200148877 A KR1020200148877 A KR 1020200148877A KR 20200148877 A KR20200148877 A KR 20200148877A KR 20220063029 A KR20220063029 A KR 20220063029A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- cachexia
- composition
- preventing
- present
- Prior art date
Links
- 206010006895 Cachexia Diseases 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000000284 extract Substances 0.000 title claims abstract description 56
- 201000011510 cancer Diseases 0.000 claims abstract description 58
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 57
- 230000001093 anti-cancer Effects 0.000 claims abstract description 26
- 208000016261 weight loss Diseases 0.000 claims abstract description 18
- 230000004580 weight loss Effects 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims description 30
- 235000013376 functional food Nutrition 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 235000013402 health food Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 13
- 210000003205 muscle Anatomy 0.000 claims description 10
- 102000003952 Caspase 3 Human genes 0.000 claims description 9
- 108090000397 Caspase 3 Proteins 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 8
- 206010061428 decreased appetite Diseases 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 31
- 230000004611 cancer cell death Effects 0.000 abstract description 5
- 244000075634 Cyperus rotundus Species 0.000 abstract description 3
- 235000016854 Cyperus rotundus Nutrition 0.000 abstract description 3
- 244000131415 Zanthoxylum piperitum Species 0.000 abstract description 3
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 16
- 208000008589 Obesity Diseases 0.000 description 14
- 235000020824 obesity Nutrition 0.000 description 14
- 238000010171 animal model Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
- 229960004316 cisplatin Drugs 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 210000000593 adipose tissue white Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- -1 olive oil Chemical compound 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 241000234646 Cyperaceae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710128942 MICOS complex subunit MIC60 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000019604 hot taste sensations Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 한약복합추출물을 포함하는 악액질 예방, 개선 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 향부자(Cyperi Rhizoma) 및 천초(Zanthoxyli Pericarpium)의 복합추출물을 포함하는 암성 악액질 예방, 개선 또는 치료용 약학적 조성물, 건강기능식품 조성물 및 항암 보조제 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving or treating cachexia comprising a herbal medicine complex extract, and more particularly, for preventing, improving or treating cancerous cachexia comprising a complex extract of Cyperi Rhizoma and Zanthoxyli Pericarpium It relates to pharmaceutical compositions, health functional food compositions, and anticancer adjuvant compositions.
악액질(cachexia)은 암, 심부전증, 만성 폐쇄성 폐 질환, 만성 신장 질환, 에이즈 등의 다양한 질병에 의해 지속적인 근육 손실을 일으키는 복잡한 증후군을 가리킨다. 이 중 암성 악액질(cancer cachexia)은 악성 종양을 수반하는 복합 대사 증후군으로서, 암이 발생하고 6개월 내에 근육과 지방의 손실에 의해 체중이 5% 이상 감소하는 것으로 정의된다. 악액질은 다양한 의학적 상태에서 일어날 수 있으나 암성 악액질은 말기 암과 밀접한 관계를 가지고 있다. 전체 암 환자의 약 50%, 특히 암 말기 환자의 약 80%가 암성 악액질의 영향을 받으며 근육 및/또는 지방의 손실로 인한 삶의 저하 및 사망률 증가로 인해 고통 받고 있다. 암성 악액질은 근육량 및/또는 지방 조직의 현저한 손실을 통한 체중 감소가 특징이며, 식욕 억제를 통한 근육 및 지방 손실과는 다른 특징을 지니고 있다.Cachexia refers to a complex syndrome that causes persistent muscle loss caused by various diseases such as cancer, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, AIDS, and the like. Among them, cancer cachexia is a complex metabolic syndrome accompanied by malignant tumors, and is defined as a loss of more than 5% in body weight due to muscle and fat loss within 6 months of the onset of cancer. Cachexia can occur in a variety of medical conditions, but cancerous cachexia is closely related to terminal cancer. About 50% of all cancer patients, particularly about 80% of those with terminal cancer, are affected by cancerous cachexia and suffer from reduced life and increased mortality due to loss of muscle and/or fat. Cancer cachexia is characterized by weight loss through significant loss of muscle mass and/or adipose tissue, and has a different characteristic than muscle and fat loss through appetite suppression.
암성악액질의 치료제에는 NSAIDs (non-steroidal anti-inflammatory drugs), β2-adrenergic agonists, corticosteroid, ghrelin 등이 있으며, 현재까지 시판되고 있는 암성 악액질 치료에 가장 많이 사용되는 약물은 COX-2 억제제와 TNF-α 억제제가 있다.Treatments for cancer cachexia include NSAIDs (non-steroidal anti-inflammatory drugs), β2-adrenergic agonists, corticosteroids, and ghrelin. There are α inhibitors.
COX-2 억제제는 암 조직에서 다량 발생되는 염증 물질인 프로스타글란딘(prostaglandins)의 생성에 관여하는 COX-2를 억제하여 골격근의 손실을 감소시키는 약물이다. COX-2 억제제로서 시중에는 셀레콕시브(celecoxib)가 판매되고 있다. 그러나 셀레콕시브(celecoxib)는 빈혈, 위궤양, 알레르기, 심장 마비 및 뇌졸중 등의 부작용이 보고되어 있다.A COX-2 inhibitor is a drug that reduces the loss of skeletal muscle by inhibiting COX-2, which is involved in the production of prostaglandins, which are inflammatory substances generated in large amounts in cancer tissues. As a COX-2 inhibitor, celecoxib is commercially available. However, side effects such as anemia, gastric ulcer, allergy, heart attack and stroke have been reported with celecoxib.
TNF-α 억제제는 암성 악액질 환자의 혈정에서 많이 발현되는 TNF-α 의 발현을 감소시켜 암세포를 사멸시키는 약물이다. TNF-α 억제제로서 시중에는 탈리도마이드(Thalidomide)가 판매되고 있다. 그러나 이들 약물은 암성 악액질 치료제로서의 효과가 적으며, 우울증, 심부전, 호흡 곤란, 구토, 발진, 고혈압 및 임신 시 기형아를 낳게 되는 부작용이 있다.A TNF-α inhibitor is a drug that kills cancer cells by reducing the expression of TNF-α, which is often expressed in the bloodstream of patients with cancer cachexia. Thalidomide is commercially available as a TNF-α inhibitor. However, these drugs have little effect as a treatment for cancer cachexia, and have side effects such as depression, heart failure, shortness of breath, vomiting, rash, high blood pressure, and birth defects during pregnancy.
이와 같이 현재까지 개발 중이거나 시판되고 있는 약물은 대부분 부작용이 많이 나타나며, 치료 효과에 대한 근거가 부족하다. 따라서 새로운 기전의 암성 악액질 치료제 개발이 절실한 상황이다.As such, most of the drugs being developed or marketed up to now have many side effects and lack of evidence for their therapeutic effect. Therefore, there is an urgent need to develop a treatment for cancer cachexia with a new mechanism.
한편, 향부자(Cyperi Rhizoma)는 사초과(Cyperaceae)에 속한 향부자(Cyperus rotundus Linne)의 뿌리줄기로서 가는 뿌리를 제거한 것을 의미하는 한약재로서, 진통작용과 자궁의 긴장성을 낮추며, 강심작용과 이뇨작용에 의해 혈액 순환을 원활하게 하는 것으로 알려져 있으며, 부인병의 선약이라 하여 통경약, 정혈약으로 월경불순, 월경통, 산전산후의 부인병에 널리 쓰인다. 또한, 해열진정약, 소화약으로 처방에 넣어 감기, 두통, 복통, 식욕저하에도 사용한다.On the other hand, Cyperi Rhizoma is a rhizome of Cyperus rotundus Linne belonging to the Cyperaceae and is an herbal medicine meaning that the thin root is removed. It is known to improve blood circulation and is widely used for menstrual irregularities, menstrual pain, and gynecological diseases before and after childbirth. In addition, it is prescribed as an antipyretic, sedative and digestive, and is used for colds, headaches, abdominal pain, and loss of appetite.
천초(Zanthoxyli Pericarpium, 川椒)는 운향과(Rutaceae)에 속한 초피나무(Zanthoxylum piperitum A.P. Dc.)의 잘 익은 열매를 말린 과피로서, 약리작용으로 국부마취작용, 장관연동작용, 항균작용 등이 보고 되었으며, 한방에서는 성미가 맵고 열이 있다 하여 비장, 위장, 신장에 작용하여 차가운 기운을 제거하는데 사용하며, 통증을 완화시키는데 사용한다.Zanthoxyli Pericarpium (Stream) is the dried pericarp of the ripe fruit of Zanthoxylum piperitum AP Dc. belonging to the Rutaceae family. In oriental medicine, it is used to relieve cold energy by acting on the spleen, stomach, and kidneys because it has a hot and spicy taste, and is used to relieve pain.
본 발명자들은 천연물인 향부자 및 천초의 복합추출물이 비만/암 동반질환 동물모델에서 암에 의한 체중감소 및 지방 손실을 억제하고, 암 세포사멸을 유도하여, 유의성 있는 항암 및 암성 악액질 개선 효과가 있음을 확인하여, 본 발명을 완성하였다.The present inventors found that the complex extracts of Hyangbuja and Cheoncho, which are natural products, have significant anticancer and cancerous cachexia improvement effects by inhibiting weight loss and fat loss caused by cancer in an animal model of obesity/cancer comorbidity, and inducing cancer cell death. By confirming, the present invention was completed.
본 발명의 목적은, 악액질(cachexia) 예방 또는 치료용 약학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for preventing or treating cachexia.
본 발명의 다른 목적은, 악액질 예방 또는 개선용 건강기능식품 조성물 및 건강식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition and health food composition for preventing or improving cachexia.
본 발명의 또 다른 목적은, 상기 약학적 조성물을 포함하는 항암 보조제 조성물을 제공하는 것이다.Another object of the present invention is to provide an anticancer adjuvant composition comprising the pharmaceutical composition.
본 발명의 또 다른 목적은, 악액질 예방 또는 치료 방법을 제공하는 것이다.Another object of the present invention is to provide a method for preventing or treating cachexia.
상기 목적을 달성하기 위하여,In order to achieve the above object,
본 발명은, 향부자(Cyperi Rhizoma) 및 천초(Zanthoxyli Pericarpium)의 복합추출물을 포함하는 악액질(cachexia) 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating cachexia comprising a complex extract of Cyperi Rhizoma and Zanthoxyli Pericarpium.
본 발명의 일실시예에 있어서, 상기 악액질은 암에 의해 유발되는 것일 수 있다.In one embodiment of the present invention, the cachexia may be caused by cancer.
또한, 본 발명은, 향부자 및 천초의 복합추출물을 포함하는 악액질 예방 또는 개선용 건강기능식품 조성물 및 건강식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition and health food composition for preventing or improving cachexia comprising a complex extract of hyangbuja and cheoncho.
나아가, 본 발명은, 상기 악액질 예방 또는 치료용 약학적 조성물을 포함하는 항암 보조제 조성물을 제공한다.Furthermore, the present invention provides an anti-cancer adjuvant composition comprising the pharmaceutical composition for preventing or treating cachexia.
더 나아가, 본 발명은 상기 악액질 예방 또는 치료용 약학적 조성물을 환자에게 투여하는 것을 포함하는 악액질 예방 또는 치료 방법을 제공한다.Furthermore, the present invention provides a method for preventing or treating cachexia comprising administering to a patient the pharmaceutical composition for preventing or treating cachexia.
본 발명의 향부자 및 천초의 복합추출물은 비만/암 동반질환 동물모델에서 암에 의한 체중 감소 및 지방 손실을 억제하고, 암 세포사멸을 유도함으로써, 유의성 있는 항암 및 암성 악액질 개선 효과를 나타내므로, 악액질 부작용 없이 항암 치료 및 악액질 개선이 동시에 가능한 암성 악액질 예방, 개선 또는 치료용 조성물로 유용할 수 있다.The complex extract of Hyangbuja and Cheoncho of the present invention suppresses weight loss and fat loss caused by cancer in an animal model of obesity/cancer comorbidity, and induces cancer cell death, thereby exhibiting significant anticancer and cancerous cachexia improvement effects. It may be useful as a composition for preventing, improving or treating cancerous cachexia, which can simultaneously improve anti-cancer treatment and cachexia without side effects.
도 1은 본 발명의 향부자 및 천초의 복합추출물 처리에 따른 비만/암 동반질환 동물모델의 7주 동안의 체중 변화(body weight change)를 나타낸 것이다.
도 2는 본 발명의 향부자 및 천초의 복합추출물 처리에 따른 비만/암 동반질환 동물모델의 체중(body weight), 암 조직의 무게(cancer weight), 피하지방(inguinal white adipose tissue, iWAT) 및 복부내장지방(epididymal white adipose tissue, eWAT)의 무게를 측정한 결과를 나타낸 것이다.
도 3은 향부자 및 천초의 복합추출물의 암 세포사멸 관련 인자(Bcl-xl, Bax, cleaved-caspase 3 및 caspase 3) 발현에 대한 효과를 나타낸 것이다.1 shows the body weight change (body weight change) for 7 weeks in an animal model of obesity/cancer comorbidity according to the treatment with the complex extract of Hyangbuja and cheoncho of the present invention.
2 is a body weight, cancer weight, subcutaneous fat (inguinal white adipose tissue, iWAT) and abdomen of an animal model of obesity/cancer comorbidity according to the treatment of the complex extract of Hyangbuja and cheoncho of the present invention. The results of measuring the weight of visceral fat (epididymal white adipose tissue, eWAT) are shown.
Figure 3 shows the effect on the expression of cancer apoptosis-related factors (Bcl-xl, Bax, cleaved-
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
악액질 예방 또는 치료용 약학적 조성물Pharmaceutical composition for preventing or treating cachexia
본 발명은 향부자(Cyperi Rhizoma) 및 천초(Zanthoxyli Pericarpium)의 복합추출물을 포함하는 악액질(cachexia) 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating cachexia comprising a complex extract of Cyperi Rhizoma and Zanthoxyli Pericarpium.
본 발명에서, 상기 향부자(Cyperi Rhizoma)는 사초과(Cyperaceae)에 속한 향부자(Cyperus rotundus Linne)의 뿌리줄기로서 가는 뿌리를 제거한 것이다.In the present invention, the hyangbuja (Cyperi Rhizoma) is a rhizome of Cyperus rotundus Linne belonging to the Cyperaceae, and the thin root is removed.
본 발명에서, 상기 천초(Zanthoxyli Pericarpium, 川椒)는 운향과(Rutaceae)에 속한 초피나무(Zanthoxylum piperitum A.P. Dc.)의 잘 익은 열매를 말린 과피이다.In the present invention, the cheoncho (Zanthoxyli Pericarpium, Stream) is the dried pericarp of the ripe fruit of Zanthoxylum piperitum AP Dc. belonging to the Rutaceae family.
본 명세서에 사용된 용어, '악액질(cachexia)'은 암, 결핵, 당뇨병, 후천성면역결핍증(Acquired immunodeficiency syndrome, AIDS) 등의 말기에서 볼 수 있는 고도의 전신쇠약증세를 말하며, 위암이나 식도암, 췌장암, 대장암 등 소화기암 환자와 폐암 환자에서 자주 나타난다. 식욕 감소, 근육 및 지방 감소에 따른 체중 및 체력의 감소, 빈혈, 무기력, 소화 불량 등의 증상 등을 나타내며, 특히 정상적으로 음식을 섭취하더라도 체중이 감소하는 상태를 나타낸다. 악액질이 발생하면 항암 화학요법이나 방사선 치료에 대해 낮은 반응을 보이므로 환자의 삶의 질이 저하되고, 기대 여명의 단축을 초래하며, 전체 암환자의 10 내지 20%에서 체중 감소로 인한 사망을 유발한다.As used herein, the term 'cachexia' refers to a high degree of general weakness that can be seen in the late stages of cancer, tuberculosis, diabetes, acquired immunodeficiency syndrome, AIDS, etc., and gastric cancer, esophageal cancer, pancreatic cancer It is frequently seen in patients with gastrointestinal cancer such as colon cancer and lung cancer. It shows symptoms such as decreased appetite, decreased body weight and stamina due to muscle and fat reduction, anemia, lethargy, indigestion, and the like. When cachexia develops, it shows a low response to chemotherapy or radiation therapy, which reduces the patient's quality of life, shortens life expectancy, and causes death due to weight loss in 10 to 20% of all cancer patients. do.
본 발명에 따른 약학적 조성물에 있어서, 상기 악액질은 암에 의해 유발되는 것일 수 있다. 본 발명의 일실시예에서는, 상기 암에 의해 유발되는 악액질을 '암성 악액질(cancer cachexia)'이라 표현하였다.In the pharmaceutical composition according to the present invention, the cachexia may be caused by cancer. In one embodiment of the present invention, cachexia induced by the cancer is expressed as 'cancer cachexia'.
본원에서 정의되는 암은 흑색종, 백혈병, 림프종, 골수종, 골수이형성증후군, 유방암, 두경부암, 식도암, 위암, 대장암(=결장암), 직장암, 항문암, 간세포간암, 담관암, 담낭암, 췌장암, 폐암(비소세포성 폐암, 소세포성 폐암), 흉선암, 신장암, 방광암, 전립선암, 고환암, 난소암, 자궁경부암, 육종, 위장관 기질성 종양(GIST, 기스트), 원발부위불명암, 중피종, 신경내분비 종양, 피부암, 혈액암 등을 포함하는 것일 수 있다.Cancer as defined herein is melanoma, leukemia, lymphoma, myeloma, myelodysplastic syndrome, breast cancer, head and neck cancer, esophageal cancer, stomach cancer, colorectal cancer (= colon cancer), rectal cancer, anal cancer, hepatocellular liver cancer, bile duct cancer, gallbladder cancer, pancreatic cancer, lung cancer (Non-small cell lung cancer, small cell lung cancer), thymus cancer, kidney cancer, bladder cancer, prostate cancer, testicular cancer, ovarian cancer, cervical cancer, sarcoma, gastrointestinal stromal tumor (GIST, GIST), cancer of unknown primary site, mesothelioma, It may include neuroendocrine tumors, skin cancers, blood cancers, and the like.
본 발명에 따른 상기 약학적 조성물은 식욕 감소, 체중 감소, 피로도 증가, 염증 증가, 근육 손실, 지방 손실 및 조혈 독성으로 이루어진 군에서 선택되는 1종 이상의 증상을 개선하는 것일 수 있고, 바람직하게는 체중 감소 및 지방 손실로 이루어진 군에서 선택되는 1종 이상의 증상을 개선하는 것일 수 있다.The pharmaceutical composition according to the present invention may be to improve one or more symptoms selected from the group consisting of decreased appetite, weight loss, increased fatigue, increased inflammation, muscle loss, fat loss, and hematopoietic toxicity, preferably body weight It may be to improve one or more symptoms selected from the group consisting of reduction and fat loss.
본 발명에 따른 상기 약학적 조성물은 항암 효과 및 암성 악액질 억제 효과를 동시에 나타내는 것일 수 있다.The pharmaceutical composition according to the present invention may simultaneously exhibit an anticancer effect and a cancerous cachexia inhibitory effect.
상기 항암 효과는 Bax 및 caspase 3로 이루어진 군으로부터 선택되는 1종 이상의 인자의 활성화를 통해 나타나는 것일 수 있고, 이를 통해 암 세포사멸 효과를 나타내는 것일 수 있다.The anticancer effect may be exhibited through the activation of one or more factors selected from the group consisting of Bax and
본 발명의 일실시예에 따르면, 향부자 및 천초의 복합추출물이 비만/암 동반질환 동물모델에서 암 조직에 의한 체중 감소 및 지방 손실을 개선시키는 효과를 보였고, 암 세포사멸의 인자로서 작용하는 Bax 및 caspase3의 발현을 활성화하는 효과 및 암을 억제하는 효과를 나타냄으로써, 항암 효과와 동시에 암성 악액질을 개선시키는 효과를 확인하였다(실험예 1 내지 3 참조).According to an embodiment of the present invention, the complex extract of Hyangbuja and Cheoncho showed an effect of improving weight loss and fat loss due to cancer tissue in an animal model of obesity/cancer comorbidity, and Bax and By showing the effect of activating the expression of caspase3 and the effect of inhibiting cancer, the effect of improving the cancer cachexia as well as the anticancer effect was confirmed (see Experimental Examples 1 to 3).
상기와 같은 효과는, 본 발명의 향부자 및 천초의 복합추출물이 각 단독 추출물 대비 효과가 현저히 증가되는 것일 수 있다.The above effect may be that the effect of the complex extract of Hyangbuja and Cheoncho of the present invention is significantly increased compared to each single extract.
본 발명에서, 상기 향부자 및 천초의 복합추출물은 향부자 및 천초를 혼합한 혼합물을 추출한 것일 수 있고, 향부자 및 천초 각각을 추출한 단독추출물을 혼합한 것일 수 있으나, 이에 제한되지는 않는다.In the present invention, the complex extract of Hyangbuja and Cheoncho may be obtained by extracting a mixture of Hyangbuja and Cheoncho, or may be a mixture of a single extract obtained by extracting each of Hyangbuja and Cheoncho, but is not limited thereto.
상기 "추출물(extract)"은 추출 대상을 적절한 침출액으로 짜내고 침출액을 증발시켜 농축한 제제를 의미하는 것으로, 이에 제한되지는 않으나, 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물일 수 있다. 상기 추출방법으로는, 이에 제한되지는 않으나, 바람직하게 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 방법을 사용할 수 있다.The "extract" refers to a preparation concentrated by squeezing the extraction target with an appropriate leachate and evaporating the leachate. It may be a dried product obtained, a crude product or a purified product thereof. The extraction method is not limited thereto, but preferably, methods such as hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction may be used.
예를 들어, 상기 복합추출물은 향부자 및 천초를 혼합하는 단계; 및 상기 혼합물을 물, C1 내지 C4의 알코올, 에틸아세테이트, 또는 이들의 혼합물로 침지하여 추출물을 수득하는 단계;를 포함하는 방법으로 제조되는 것일 수 있으나, 이에 제한되지는 않는다. 이때, 상기 C1 내지 C4의 알코올은 에탄올, 메탄올, 부탄올, 또는 이들의 조합일 수 있다. 상기 추출용매를 향부자 및 천초 혼합물 중량의 1 내지 10배 부피의 양으로 첨가하여 추출하는 것일 수 있다. 추출온도는 30 내지 120℃인 것일 수 있으나, 이에 한정되는 것은 아니다. 또한, 추출시간은 2 내지 48시간인 것일 수 있으나, 이에 한정되는 것은 아니다. For example, the complex extract comprises the steps of mixing Hyangbuja and Cheoncho; and immersing the mixture in water, C1 to C4 alcohol, ethyl acetate, or a mixture thereof to obtain an extract; may be prepared by a method comprising, but is not limited thereto. In this case, the C1 to C4 alcohol may be ethanol, methanol, butanol, or a combination thereof. The extraction may be performed by adding the extraction solvent in an amount of 1 to 10 times the weight of the mixture of Hyangbuja and Cheoncho. The extraction temperature may be 30 to 120 ℃, but is not limited thereto. In addition, the extraction time may be 2 to 48 hours, but is not limited thereto.
상기 향부자 및 천초는 0.1:10~10:0.1의 중량비로 혼합하는 것일 수 있고, 바람직하게는 0.5:5~5:0.5의 중량비로 혼합하는 것일 수 있고, 더 바람직하게는 1:3~3:1의 중량비로 혼합하는 것일 수 있고, 1:2~2:1의 중량비로 혼합하는 것이 가장 바람직한 것일 수 있다.The hyangbuja and cheoncho may be mixed in a weight ratio of 0.1:10 to 10:0.1, preferably mixed in a weight ratio of 0.5:5 to 5:0.5, more preferably 1:3 to 3: It may be mixed in a weight ratio of 1, and mixing in a weight ratio of 1:2 to 2:1 may be the most preferable.
상기 추출방법은 추출물을 물, C1 내지 C4 알코올, 또는 이들의 조합으로 분획하는 단계를 더 포함할 수 있다. 바람직하게는, 물, 에탄올, 메탄올, 부탄올, 에틸아세테이트, 헥산 또는 이들의 조합으로 분획될 수 있다. 상기 추출방법은 추출물을 농축, 원심분리, 여과, 흡착, 또는 크로마토그래피를 수행하는 단계를 더 포함할 수 있다.The extraction method may further include fractionating the extract with water, C1 to C4 alcohol, or a combination thereof. Preferably, it may be fractionated with water, ethanol, methanol, butanol, ethyl acetate, hexane, or a combination thereof. The extraction method may further include performing concentration, centrifugation, filtration, adsorption, or chromatography on the extract.
본 발명에 따른 상기 약학적 조성물은 경구 투여용, 근육내 투여용, 정맥내 투여용, 복강내 투여용, 피하 투여용, 피내 투여용, 또는 국소 투여용으로 제제화되는 것일 수 있다.The pharmaceutical composition according to the present invention may be formulated for oral administration, intramuscular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, intradermal administration, or topical administration.
본 발명의 향부자 및 천초의 복합추출물은 임상 투여시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있으며, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 제조된다.The complex extract of Hyangbuja and Cheoncho of the present invention may be administered in various oral and parenteral formulations during clinical administration, and in the case of formulation, commonly used fillers, extenders, binders, wetting agents, disintegrants, diluents such as surfactants, etc. or using an excipient.
경구투여를 위한 고형 제제에는 정제, 환자, 산제, 과립제, 캡슐제, 트로키제 등이 포함되며, 이러한 고형 제제는 하나 이상의 본 발명의 향부자 및 천초의 복합추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로스(sucrose), 락토오스(lactose) 또는 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제 또는 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, patients, powders, granules, capsules, troches, etc., and these solid preparations include at least one excipient, such as starch , calcium carbonate, sucrose, lactose, or gelatin is mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid formulations for oral administration include suspensions, solutions, emulsions, or syrups. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. can
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁용제, 유제, 동결건조제제, 좌제 등이 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤, 젤라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspension solutions, emulsions, lyophilized formulations, suppositories, and the like. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, and the like can be used.
상기 약학적 조성물은 담체, 부형제 또는 희석제를 더 포함할 수 있다. 담체, 부형제, 또는 희석제는 예를 들어, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알기네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로스, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 또는 광물유를 포함할 수 있다.The pharmaceutical composition may further include a carrier, excipient or diluent. Carriers, excipients, or diluents include, for example, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil.
또한, 상기 약학적 조성물은 암성 악액질 예방 또는 치료 활성을 갖는 공지의 유효성분을 더 포함할 수 있다.In addition, the pharmaceutical composition may further include a known active ingredient having a preventive or therapeutic activity for cancer cachexia.
본 발명의 향부자 및 천초의 복합추출물의 인체에 대한 효과적인 투여량은 환자의 나이, 몸무게, 성별, 투여형태, 건강상태 및 질환 정도에 따라 달라질 수 있으며, 일반적으로 약 0.001~100 mg/kg/일이며, 바람직하게는 0.01~35 mg/kg/일이다. 몸무게가 70 ㎏인 성인 환자를 기준으로 할 때, 일반적으로 0.07~7000 mg/일이며, 바람직하게는 0.7~2500 ㎎/일이며, 의사 또는 약사의 판단에 따라 일정시간 간격으로 1일 1회 내지 수회로 분할 투여할 수도 있다.The effective dosage for the human body of the complex extract of Hyangbuja and Cheoncho of the present invention may vary depending on the patient's age, weight, sex, dosage form, health condition and disease level, and is generally about 0.001 to 100 mg/kg/day and preferably 0.01 to 35 mg/kg/day. Based on an adult patient weighing 70 kg, it is generally 0.07 to 7000 mg/day, preferably 0.7 to 2500 mg/day, and once a day at regular time intervals according to the judgment of a doctor or pharmacist It may be administered in several divided doses.
악액질 예방 또는 개선용 건강기능식품 및 건강식품 조성물Health functional food and health food composition for preventing or improving cachexia
또한, 본 발명은 향부자(Cyperi Rhizoma) 및 천초(Zanthoxyli Pericarpium)의 복합추출물을 포함하는 악액질(cachexia) 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving cachexia comprising a complex extract of Hyangbuja (Cyperi Rhizoma) and Zanthoxyli Pericarpium.
나아가, 본 발명은 향부자(Cyperi Rhizoma) 및 천초(Zanthoxyli Pericarpium)의 복합추출물을 포함하는 악액질(cachexia) 예방 또는 개선용 건강식품 조성물을 제공한다.Furthermore, the present invention provides a health food composition for preventing or improving cachexia comprising a complex extract of Hyangbuja (Cyperi Rhizoma) and Zanthoxyli Pericarpium.
본 발명에 따른 건강기능식품 조성물 또는 건강식품 조성물에 있어서, 상기 악액질은 암에 의해 유발되는 것일 수 있다.In the health functional food composition or health food composition according to the present invention, the cachexia may be caused by cancer.
본 발명에 따른 건강기능식품 조성물 또는 건강식품 조성물은 식욕 감소, 체중 감소, 피로도 증가, 염증 증가, 근육 손실, 지방 손실 및 조혈 독성으로 이루어진 군에서 선택되는 1종 이상의 증상을 개선하는 것일 수 있고, 바람직하게는 체중 감소 및 지방 손실로 이루어진 군에서 선택되는 1종 이상의 증상을 개선하는 것일 수 있다.The health functional food composition or health food composition according to the present invention may improve one or more symptoms selected from the group consisting of decreased appetite, weight loss, increased fatigue, increased inflammation, muscle loss, fat loss, and hematopoietic toxicity, Preferably, it may be to improve one or more symptoms selected from the group consisting of weight loss and fat loss.
본 발명에 따른 건강기능식품 조성물 또는 건강식품 조성물은 항암 효과 및 암성 악액질 억제 효과를 동시에 나타내는 것일 수 있다.The health functional food composition or health food composition according to the present invention may simultaneously exhibit an anticancer effect and a cancerous cachexia inhibitory effect.
상기 항암 효과는 Bax 및 caspase 3로 이루어진 군으로부터 선택되는 1종 이상의 인자의 활성화를 통해 나타나는 것일 수 있다. 바람직하게는 caspase cascade 활성화에 의해 암 세포사멸 효과를 나타내는 것일 수 있다.The anticancer effect may be shown through activation of one or more factors selected from the group consisting of Bax and
본 발명의 일실시예에 따르면, 향부자 및 천초의 복합추출물이 비만/암 동반질환 동물모델에서 암 조직에 의한 체중 감소 및 지방 손실을 개선시키는 효과를 보였고, 암 세포사멸의 인자로서 작용하는 Bax 및 caspase3의 발현을 활성화하는 효과 및 암을 억제하는 효과를 나타냄으로써, 항암 효과와 동시에 암성 악액질을 개선시키는 효과를 확인하였다(실험예 1 내지 3 참조).According to an embodiment of the present invention, the complex extract of Hyangbuja and Cheoncho showed an effect of improving weight loss and fat loss due to cancer tissue in an animal model of obesity/cancer comorbidity, and Bax and By showing the effect of activating the expression of caspase3 and the effect of inhibiting cancer, the effect of improving the cancer cachexia as well as the anticancer effect was confirmed (see Experimental Examples 1 to 3).
본 발명에서 사용되는 용어 "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캡슐제, 환제, 액제, 분말 및 과립 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 '기능성'이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 통상의 기술분야에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조시에는 통상의 기술분야에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한, 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한없이 제조될 수 있다. 본 발명의 건강기능식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 암성 악액질 치료제 또는 항암제의 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The term "health functional food" used in the present invention refers to food manufactured and processed in the form of tablets, capsules, pills, liquids, powders and granules, etc. using raw materials or ingredients useful for the human body. Here, 'functionality' refers to obtaining useful effects for health purposes, such as regulating nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be manufactured by a method commonly used in the ordinary technical field, and at the time of the preparation, it can be prepared by adding raw materials and components commonly added in the conventional technical field. In addition, the dosage form of the health functional food may also be manufactured without limitation as long as it is a dosage form recognized as a health functional food. The health functional food composition of the present invention can be prepared in various types of dosage forms, and unlike general drugs, it has the advantage of not having side effects that may occur during long-term administration of drugs using food as a raw material, and has excellent portability, The health functional food of the present invention can be ingested as an adjuvant for enhancing the effect of a cancer cachexia therapeutic agent or an anticancer agent.
본 발명에 따른 상기 건강기능식품 조성물 또는 건강식품 조성물은 암성 악액질을 예방 또는 개선시키기 위한 목적으로 상기 향부자 및 천초의 복합추출물을 식품, 음료 등의 건강기능식품 또는 건강식품에 첨가할 수 있다.The health functional food composition or health food composition according to the present invention can be added to health functional food or health food, such as food, beverage, etc. for the purpose of preventing or improving cancerous cachexia.
상기 식품의 종류에는 특별한 제한은 없다. 본 발명에 따른 향부자 및 천초의 복합추출물을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소시지, 빵, 비스킷, 떡, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제, 유제품 및 유가공 제품 등이 있으며, 통상적인 의미에서의 건강식품 및 건강기능식품을 모두 포함한다.There is no particular limitation on the type of the food. Examples of foods to which the complex extract of Hyangbuja and Cheoncho according to the present invention can be added include drinks, meat, sausages, bread, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice creams Dairy products, various soups, beverages, alcoholic beverages and vitamin complexes, dairy products and dairy products including
본 발명에 따른 상기 건강기능식품 및 건강식품 조성물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 본 발명에 따른 상기 향부자 및 천초의 복합추출물의 혼합량은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강식품 및 건강기능식품 중의 상기 향부자 및 천초의 복합추출물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 유지를 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The health functional food and health food composition according to the present invention may be added to food as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the complex extract of Hyangbuja and Cheoncho according to the present invention may be suitably determined according to the purpose of its use (for prevention or improvement). In general, the amount of the complex extract of hyangbuja and cheoncho in health food and health functional food may be added in an amount of 0.1 to 90 parts by weight of the total food weight. However, in the case of long-term intake for health maintenance or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.
본 발명의 건강식품 및 건강기능식품 조성물은 지시된 비율로 필수 성분으로서 본 발명에 따른 향부자 및 천초의 복합추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트라이톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강기능성 식품 조성물 100 g당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health food and health functional food composition of the present invention is not particularly limited in other ingredients except for containing the complex extract of Hyangbuja and cheoncho according to the present invention as an essential ingredient in the indicated ratio, and various flavoring agents or natural Carbohydrates and the like may be contained as additional ingredients. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 g of the dietary supplement of the present invention.
상기 외에 본 발명에 따른 향부자 및 천초의 복합추출물을 함유하는 건강식품 및 건강기능식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강식품 및 건강기능식품 조성물은 천연 과일쥬스 및 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition to the above, the health food and health functional food composition containing the complex extract of Hyangbuja and Cheoncho according to the present invention are various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and thickening agents. (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated drinks, etc. . In addition, the health food and health functional food composition of the present invention may contain natural fruit juice, fruit juice, and fruit for the production of a vegetable drink.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 이에 제한되지는 않으나, 본 발명의 유효물질을 함유하는 건강식품 및 건강기능식품 조성물 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.These components may be used independently or in combination. The proportion of these additives is not limited thereto, but is generally selected from 0.1 to about 20 parts by weight per 100 parts by weight of the health food and health functional food composition containing the active substance of the present invention.
항암 보조제 조성물Anti-cancer adjuvant composition
또한, 본 발명은 상기 본 발명에 따른 악액질(cachexia) 예방 또는 치료용 약학적 조성물을 포함하는 항암 보조제 조성물을 제공한다.In addition, the present invention provides an anti-cancer adjuvant composition comprising the pharmaceutical composition for preventing or treating cachexia according to the present invention.
본 발명에서 사용되는 용어 "항암보조제"는 항암 치료 효과를 증대시키고, 항암제의 부작용을 억제하거나 개선시키기 위하여 사용될 수 있으며, 항암제와 병용하여 환자에게 투여될 수 있다.The term "anticancer adjuvant" used in the present invention may be used to increase the anticancer therapeutic effect, suppress or improve the side effects of anticancer agents, and may be administered to a patient in combination with an anticancer agent.
본 발명의 상기 항암 보조제 조성물은, 암에 의해 유발되는 근손실, 체중 감소, 지방 감소, 조혈 도성, 식욕 감소 등의 악액질 증상을 억제하거나 개선시키는 효과를 나타내어 항암제의 항암효과를 증대시키는 것일 수 있다.The anticancer adjuvant composition of the present invention exhibits an effect of suppressing or improving cachexia symptoms such as muscle loss, weight loss, fat reduction, hematopoiesis, and decreased appetite caused by cancer, thereby increasing the anticancer effect of the anticancer agent. .
본원에서 정의되는 기존 항암제는 시스플라틴(cisplatin), 시클로포스파미드(Cyclophosphamide), 메토트랙세이트 (methotrexate), 5-플루오로우라실(fluorouracil), 독소루비신(Doxorubicin), 무스틴(Mustine), 비크리스틴(vincristine), 프로카바진(procarbazine), 프레드니솔론(prednisolone), 블레오마이신(bleomycin), 빈블라스틴(vinblastine), 다카르바진(dacarbazine), 에토포시드 (etoposide), 에피루비신(Epirubicin), 시스플라틴(cisplatin), 카페시타빈(capecitabine), 옥살리플라틴(oxaliplatin) 등을 포함하는 것일 수 있다.Existing anticancer agents as defined herein include cisplatin, cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, mustine, vicristine ( vincristine), procarbazine, prednisolone, bleomycin, vinblastine, dacarbazine, etoposide, epirubicin, cisplatin ( cisplatin), capecitabine, oxaliplatin, and the like.
상기 항암 보조제 조성물은 유효성분으로 향부자 및 천초의 복합추출물을 포함하는 이외에 동일 또는 유사한 기능을 나타내는 유효성분을 추가로 1종 이상 포함할 수 있다. 상기 항암 보조제는 임상 투여 시에 경구 또는 비경구로 투여가 가능하며, 비경구 투여 시 복강 내 주사, 직장 내 주사, 피하주사, 정맥주사, 근육 내 주사, 자궁 내 경막주사, 뇌혈관 내 주사 또는 흉부 내 주사에 의해 투여될 수 있고, 일반적인 의약품 제제의 형태로 사용될 수 있다.The anti-cancer adjuvant composition may further include one or more active ingredients exhibiting the same or similar functions in addition to including the complex extract of Hyangbuja and Cheoncho as active ingredients. The anticancer adjuvant can be administered orally or parenterally during clinical administration, and when administered parenterally, intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine dural injection, intracerebrovascular injection, or thoracic It can be administered by internal injection, and can be used in the form of general pharmaceutical preparations.
상기 항암 보조제는 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다. 상기 항암 보조제의 일일 투여량은 약 0.0001 내지 1000 ㎎/㎏이고, 바람직하게는 1 내지 100 ㎎/㎏이며, 하루 1회 내지 수회 나누어 투여하는 것이 바람직하나 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여 방법, 배설률 및 질환의 중증도 등에 따라 그 범위가 다양하다. 본 발명의 항암 보조제는 실제 임상 투여 시에 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The anticancer adjuvant may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers. The daily dose of the anticancer adjuvant is about 0.0001 to 1000 mg/kg, preferably 1 to 100 mg/kg, and it is preferable to divide and administer it once to several times a day, but the patient's weight, age, sex, health condition, The range varies depending on the diet, administration time, administration method, excretion rate, and the severity of the disease. The anticancer adjuvant of the present invention may be administered in various parenteral formulations during actual clinical administration. When formulated, a diluent or excipient such as a commonly used filler, extender, binder, wetting agent, disintegrant, surfactant, etc. is prepared Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.
또한, 본 발명은 상기 본 발명에 따른 악액질(cachexia) 예방 또는 치료용 약학적 조성물을 환자에게 투여하는 것을 포함하는 악액질(cachexia) 예방 또는 치료 방법을 제공한다.The present invention also provides a method for preventing or treating cachexia, comprising administering to a patient the pharmaceutical composition for preventing or treating cachexia according to the present invention.
본 발명의 치료 방법은 상기 약학적 조성물을 치료적 유효량으로 개체에 투여하는 것을 포함한다. 특정 개체에 대한 구체적인 치료적 유효량은 달성하고자 하는 반응의 종류와 정도, 경우에 따라 다른 제제가 사용되는지의 여부를 비롯한 구체적 조성물, 개체의 연령, 체중, 일반건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다. 따라서 본 발명의 목적에 적합한 조성물의 유효량은 전술한 사항을 고려하여 결정하는 것이 바람직하다.The treatment method of the present invention comprises administering the pharmaceutical composition to a subject in a therapeutically effective amount. A specific therapeutically effective amount for a particular subject will depend on the type and extent of the response to be achieved, the specific composition, including whether other agents are used, if necessary, the subject's age, weight, general health, sex and diet, time of administration; It is preferable to apply differently depending on various factors including the route of administration and secretion rate of the composition, the duration of treatment, the drug used together with or concurrently with the specific composition, and similar factors well known in the pharmaceutical field. Therefore, it is preferable to determine the effective amount of the composition suitable for the purpose of the present invention in consideration of the foregoing.
상기 환자는 임의의 포유동물에 적용가능하며, 상기 포유동물은 인간 및 영장류뿐만 아니라, 소, 돼지, 양, 말, 개 및 고양이 등의 가축을 포함한다.The patient is applicable to any mammal, and the mammal includes not only humans and primates, but also domestic animals such as cattle, pigs, sheep, horses, dogs and cats.
본 발명의 상기 악액질 예방 또는 치료 방법은, 암에 의해 유발되는 악액질 및 암을 동시에 예방 또는 치료하는 방법인 것일 수 있다.The method for preventing or treating cachexia of the present invention may be a method for simultaneously preventing or treating cachexia and cancer caused by cancer.
이하, 본 발명을 하기의 실시예에 의하여 더욱 상세하게 설명한다. 단, 하기의 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기의 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following examples.
<실시예 1> 향부자 및 천초의 복합추출물의 제조<Example 1> Preparation of complex extracts of Hyangbuja and Cheoncho
향부자(Cyperi Rhizoma) 및 천초(Zanthoxyli Pericarpium)를 포함하는 한약 복합추출물은 향부자 및 천초를 1:1의 중량비로 혼합하여 열수추출하여 제조하였다. 구체적으로, 향부자 및 천초 약재를 손질하여 세척한 후 향부자 250 g과 천초 250 g을 혼합하여, 증류수 1L에 넣고, 100℃에서 2시간 동안 전탕하여 500 ml이 되도록 하였다. 전탕액은 동결 건조하여 분말 형태의 향부자 및 천초 복합추출물(실시예 1, HC)을 제조하였다. Herbal medicine complex extract containing Hyangbuja (Cyperi Rhizoma) and Zanthoxyli Pericarpium was prepared by hot water extraction by mixing Hyangbuja and Chuncho in a weight ratio of 1:1. Specifically, after cleaning and washing the medicinal herbs of Hyangbuja and Cheoncho, 250 g of Hyangbuja and 250 g of Cheoncho were mixed, put in 1 L of distilled water, and heated at 100° C. for 2 hours to make 500 ml. The Jeontang solution was freeze-dried to prepare a powdered hyangbuja and cheoncho complex extract (Example 1, HC).
또한, 향부자 500g 및 천초 500g 각각을 상기와 동일한 방법을 이용하여, 향부자 단일 추출물 및 천초 단일 추출물을 제조하였다.In addition, using the same method as above for each of 500 g of Hyangbuja and 500g of cheoncho, a single extract of Hyangbuja and a single extract of cheoncho was prepared.
이때, 천초 및 향부자 추출물 각각의 수율은 15.70% 및 14.15%이었다. 상기 추출물 분말은 각각 3차 증류수에 녹인 후, 22 μm의 필터로 여과하여 실험에 사용하였다.At this time, the yields of each of the extracts of Cheoncho and Hyangbuja were 15.70% and 14.15%. Each of the extract powders was dissolved in tertiary distilled water, and then filtered through a 22 μm filter and used in the experiment.
<실험예 1> 동물 모델의 준비<Experimental Example 1> Preparation of animal models
본 발명의 추출물의 암성 악액질에 대한 효과를 확인하기 위해, 비만/암 동반 질환 동물모델을 제조하였다.In order to confirm the effect of the extract of the present invention on cancer cachexia, an animal model of obesity/cancer comorbidity was prepared.
구체적으로, 7주령의 C57bl/6j 마우스에 5주 동안 고지방식이를 섭취시킨 후 5주차에 마우스 왼쪽 허벅지에 C57bl/6j 유래 흑색종세포인 B16BL6 세포를 피하주사하여 암(흑색종) 및 비만을 유발하였다. 이 후 추가적으로 2주 동안 모든 그룹에 고지방식이를 먹이면서, 실시예 1의 향부자 및 천초 복합추출물(HC; 경구투여, 주3회) 또는 흑색종 치료에 많이 사용되는 항암제인 시스플라틴(cisplatin, CIS; 복강투여, 주1회)을 투여하였다. 대조군(high fat diet, HFD) 및 질병대조군(HFD+B16BL6 injection)에는 각각 비만 또는 비만/암 유발 후 2주 동안 아무것도 주입하지 않고 고지방식이만 섭취시켰다.Specifically, 7-week-old C57bl/6j mice were fed a high-fat diet for 5 weeks, and then at the 5th week, C57bl/6j-derived melanoma cells, B16BL6 cells, were subcutaneously injected into the left thigh of the mouse to prevent cancer (melanoma) and obesity. induced. After that, while feeding all groups a high-fat diet for an additional 2 weeks, the Hyangbuja and Chinese herbal medicine complex extract of Example 1 (HC; oral administration, 3 times a week) or cisplatin (cisplatin, CIS), an anticancer agent widely used in the treatment of melanoma ; intraperitoneal administration, once a week) was administered. Control group (high fat diet, HFD) and disease control group (HFD+B16BL6 injection) were ingested only high fat diet without injecting anything for 2 weeks after induction of obesity or obesity/cancer, respectively.
<실험예 2> 복합추출물의 암성 악액질에 의한 체중 감소 개선 효과<Experimental Example 2> Weight loss improvement effect by cancer cachexia of the complex extract
암성 악액질의 유발 및 복합추출물의 개선 효과를 확인하기 위해 상기 실시예 1과 같은 방법으로 총 7주간의 처치 기간 동안 마우스들의 체중 변화(body weight change)를 측정하여 도 1에 나타내었다. 또한, 암 조직에 따른 체중의 차이를 보정하기 위해 총 7주간의 처치 후 전체 체중(body weight), 암 조직의 무게(cancer weight), 백색지방조직인 피하지방(inguinal white adipose tissue, iWAT) 및 복부내장지방(epididymal white adipose tissue, eWAT)의 무게를 각각 측정하여 비교하였다. 각 무게의 측정 결과는 도 2에 나타내었다.In order to confirm the induction of cancerous cachexia and the improvement effect of the complex extract, the body weight change of the mice was measured during the treatment period for a total of 7 weeks in the same manner as in Example 1, and is shown in FIG. In addition, in order to correct the difference in body weight according to cancer tissue, total body weight, cancer weight, white adipose tissue (inguinal white adipose tissue, iWAT) and abdomen after a total of 7 weeks of treatment The weights of visceral fat (epididymal white adipose tissue, eWAT) were respectively measured and compared. The measurement results of each weight are shown in FIG. 2 .
그 결과, 도 1 및 도 2에 나타난 바와 같이, 암이 비유발된 대조군(HFD)에서는 고지방식이 섭취에 의해 체중 및 백색지방조직 무게가 증가한 반면, 비만/암 동반 유발된 질병대조군(HFD+B16BL6 injection)에서는 전체 체중이 상대적으로 감소되는 것이 관찰되었으며, 특히, 항암제인 시스플라틴(CIS)을 처리한 군의 경우, 질병대조군보다도 체중이 감소되는 것으로 나타났다. 또한, 도 2에 나타난 바와 같이, 암 조직을 제외한 체중 및 백색지방조직 무게가 대조군(HFD) 대비 질병대조군(HFD+B16BL6 injection)에서 현저히 감소되었다. 이러한 결과로부터, 비만/암 동반질환 동물모델에서 암성 악액질이 유발되었음을 확인하였으며, 항암제 처리시 암성 악액질이 개선되지 않고 오히려 체중 감소 현상이 증가되는 것을 확인하였다.As a result, as shown in FIGS. 1 and 2 , in the non-cancerous control group (HFD), body weight and white adipose tissue weight increased by ingestion of a high-fat diet, whereas the obesity/cancer-induced disease control group (HFD+) B16BL6 injection), it was observed that the total body weight was relatively decreased, and in particular, in the case of the group treated with the anticancer drug cisplatin (CIS), it was found that the body weight was decreased compared to the disease control group. In addition, as shown in FIG. 2 , body weight and white adipose tissue weight excluding cancer tissues were significantly reduced in the disease control group (HFD+B16BL6 injection) compared to the control group (HFD). From these results, it was confirmed that cancer cachexia was induced in the animal model of obesity/cancer comorbidity, and it was confirmed that the cancer cachexia was not improved but rather the weight loss phenomenon was increased when the anticancer drug was treated.
한편, 비만/암 동반질환 동물모델에서 대조군(HFD) 대비 질병대조군(HFD+B16BL6 injection)의 체중(body weight)은 16% 현저하게 감소한 반면에, 실시예 1의 복합추출물(HC)을 처리하였을 때는 이러한 체중 감소가 억제되어 대조군과 유사한 수준으로 증가되었다(도 2A). 피하지방(iWAT) 및 복부내장지방(eWAT) 무게의 경우에도, 실시예 1의 복합추출물(HC)을 처리하였을 때, 질병대조군(HFD+B16BL6 injection) 대비 암 조직에 의한 지방 감소가 현저하게 억제되어, 대조군(HFD)과 유사하게 무게가 유지되었음을 확인하였다(도 2C 및 도 2D).On the other hand, the body weight of the control group (HFD+B16BL6 injection) compared to the control group (HFD) in the animal model of obesity/cancer comorbidity was significantly reduced by 16%, whereas the complex extract (HC) of Example 1 was treated. This weight loss was suppressed and increased to a level similar to that of the control group (FIG. 2A). Even in the case of subcutaneous fat (iWAT) and abdominal visceral fat (eWAT) weight, when the complex extract (HC) of Example 1 was treated, fat reduction by cancer tissue was significantly inhibited compared to the disease control group (HFD+B16BL6 injection) It was confirmed that the weight was maintained similar to that of the control (HFD) ( FIGS. 2C and 2D ).
또한, 비만/암 동반질환 동물모델에서 실시예 1의 복합추출물(HC)을 처리하였을 때, 질병대조군 대비 암 조직의 무게(cancer weight)를 유의적으로(p<0.05) 감소시켰다(도 2B). In addition, when the complex extract (HC) of Example 1 was treated in the animal model of obesity/cancer comorbidity, the weight of cancer tissue compared to the disease control group was significantly (p<0.05) reduced (Fig. 2B) .
결과적으로, 항암제인 시스플라틴은 암 조직 증가는 억제할 수 있으나, 암 조직에 의한 체중 감소 및 지방 감소는 억제할 수 없고 오히려 더 악화되는 반면, 본 발명의 실시예 1의 복합추출물(HC)은 우수한 항암 효과를 나타내면서도 암 조직에 의한 체중 감소 및 지방 감소를 현저히 억제함으로써, 암성 악액질에 대해 우수한 억제 효과를 나타냄을 확인하였다. As a result, the anticancer agent cisplatin can inhibit the increase in cancer tissue, but cannot suppress the weight loss and fat loss caused by the cancer tissue, but rather worsen it, whereas the complex extract (HC) of Example 1 of the present invention is excellent It was confirmed that it exhibits an excellent inhibitory effect on cancerous cachexia by significantly inhibiting weight loss and fat loss caused by cancer tissue while exhibiting an anticancer effect.
<실험예 3> 복합추출물의 암 세포사멸 지표 인자 발현에 대한 효과<Experimental Example 3> Effects of complex extracts on the expression of cancer apoptosis indicator factors
상기 동물 모델의 암 조직에서 본 발명의 실시예 1의 복합추출물(HC)이 세포사멸(apoptosis)인자 발현에 미치는 효과를 측정하기 위해, 미토콘드리아 내막 및 외막 단백질인 Bcl-family 중 대표적으로 Bcl-xl 및 Bax의 발현량 및 세포사멸의 주요 기전인 caspase cascade에서 대표적으로 caspase 3의 발현량의 변화를 웨스턴 블랏(Western blot)을 이용하여 확인하였다. In order to measure the effect of the complex extract (HC) of Example 1 of the present invention on the expression of apoptosis factors in the cancer tissue of the animal model, representative of the mitochondrial inner and outer membrane proteins, Bcl-family, Bcl-xl And the change in the expression level of
상기 동물 모델의 암 조직 세포를 RIPA 버퍼 [50 mM Tris-HCl (pH 7.5), 0.1% 소듐 도데실 설페이트(sodium dodecyl sulphate, SDS), 0.1% Triton X-100, 1% Nonidet P-40, 0.5% 소듐 데옥시콜레이트(sodium deoxycholate), 150 mM NaCl 및 1 mM 페닐메틸설포닐 플루오라이드(phenylmethylsulphonyl fluoride)]로 용해시킨 후, 8% 소듐 도데실 설페이트-폴리아크릴아마이드 겔(sodium dodecyl sulfatepolyacrylamide gel) 전기 영동으로 분리하고 나이트로셀룰로스(nitrocellulose) 멤브레인으로 옮겼다. 멤브레인은 실온에서 1시간 동안 5% 탈지유가 함유된 TBST(10mM Tris, 150mM NaCl 및 0.05% Tween20, pH 7.6)로 블로킹하고, TBST로 세척 한 후, Bax, Bcl-xL, Caspase 3(Thermo Scientific, Waltham, MA, USA) 또는 액틴(β-actin, Santa Cruz Biotechnology, Inc.) 1차 항체와 함께 4℃에서 밤새동안 배양하였다. 이어서 멤브레인을 실온에서 2시간 동안 적절한 horseradish peroxidase (Jackson Lab.)가 부착된 2차 항체(Amersham Biosciences, Westborough, MA, USA)와 반응시켰다. 목적 단백질 밴드는 제조자의 지시에 따라 강화된 화학발광(enhanced chemiluminescence, ECL) 용액(Amersham Bioscience, Piscataway, NJ)을 사용하여 LAS 이미지 게이지(LAS Image Gauge) 프로그램에서 측정하였으며, 그 결과를 도 3에 나타내었다. The cancer tissue cells of the animal model were treated with RIPA buffer [50 mM Tris-HCl (pH 7.5), 0.1% sodium dodecyl sulphate, SDS), 0.1% Triton X-100, 1% Nonidet P-40, 0.5 % sodium deoxycholate, 150 mM NaCl and 1 mM phenylmethylsulphonyl fluoride], followed by 8% sodium dodecyl sulfate-polyacrylamide gel electrolysis It was separated by electrophoresis and transferred to a nitrocellulose membrane. The membranes were blocked with TBST (10 mM Tris, 150 mM NaCl and 0.05% Tween20, pH 7.6) with 5% skim milk at room temperature for 1 h, washed with TBST, and then Bax, Bcl-xL, Caspase 3 (Thermo Scientific, Waltham, MA, USA) or actin (β-actin, Santa Cruz Biotechnology, Inc.) were incubated overnight at 4°C with primary antibodies. Then, the membrane was reacted with a secondary antibody (Amersham Biosciences, Westborough, MA, USA) to which an appropriate horseradish peroxidase (Jackson Lab.) was attached at room temperature for 2 hours. The target protein band was measured in the LAS Image Gauge program using an enhanced chemiluminescence (ECL) solution (Amersham Bioscience, Piscataway, NJ) according to the manufacturer's instructions, and the results are shown in FIG. indicated.
그 결과, 도 3에 나타난 바와 같이, 질병대조군 대비 복합추출물(HC) 처리군에서 Bax/Bcl-xL 및 cleaved/ pro caspase 3의 비율이 증가한 것으로 보아 이들 인자의 활성화를 통한 암 억제효과가 있는 것을 확인하였다.As a result, as shown in Figure 3, the ratio of Bax / Bcl-xL and cleaved /
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허 청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, the present invention has been looked at with respect to preferred embodiments thereof. Those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments are to be considered in an illustrative rather than a restrictive sense. The scope of the present invention is indicated in the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.
Claims (12)
상기 악액질은 암에 의해 유발되는 것인, 약학적 조성물.According to claim 1,
The cachexia is caused by cancer, the pharmaceutical composition.
상기 조성물은 식욕 감소, 체중 감소, 피로도 증가, 염증 증가, 근육 손실, 지방 손실 및 조혈 독성으로 이루어진 군에서 선택되는 1종 이상의 증상을 개선하는 것인, 약학적 조성물.According to claim 1,
The composition is to improve one or more symptoms selected from the group consisting of decreased appetite, weight loss, increased fatigue, increased inflammation, muscle loss, fat loss, and hematopoietic toxicity.
상기 조성물은 체중 감소 및 지방 손실로 이루어진 군에서 선택되는 1종 이상의 증상을 개선하는 것인, 약학적 조성물.4. The method of claim 3,
The composition is to improve one or more symptoms selected from the group consisting of weight loss and fat loss, a pharmaceutical composition.
상기 조성물은 항암 효과 및 암성 악액질 억제 효과를 동시에 나타내는 것인, 약학적 조성물.According to claim 1,
The composition will exhibit the anticancer effect and the cancer cachexia inhibitory effect at the same time, the pharmaceutical composition.
상기 항암 효과는 Bax 및 caspase 3로 이루어진 군으로부터 선택되는 1종 이상의 인자의 활성화를 통해 나타나는 것인, 약학적 조성물.6. The method of claim 5,
The anticancer effect will appear through the activation of one or more factors selected from the group consisting of Bax and caspase 3, the pharmaceutical composition.
상기 악액질은 암에 의해 유발되는 것인, 건강기능식품 조성물.8. The method of claim 7,
The cachexia is a health functional food composition that is caused by cancer.
상기 악액질은 암에 의해 유발되는 것인, 건강식품 조성물.10. The method of claim 9,
The cachexia is caused by cancer, health food composition.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200148877A KR102477343B1 (en) | 2020-11-09 | 2020-11-09 | Composition for preventing or treating cachexia comprising medicinal herb complex extract |
PCT/KR2021/016150 WO2022098192A1 (en) | 2020-11-09 | 2021-11-08 | Composition for preventing or treating cachexia comprising medicinal herb complex extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200148877A KR102477343B1 (en) | 2020-11-09 | 2020-11-09 | Composition for preventing or treating cachexia comprising medicinal herb complex extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220063029A true KR20220063029A (en) | 2022-05-17 |
KR102477343B1 KR102477343B1 (en) | 2022-12-13 |
Family
ID=81458187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200148877A KR102477343B1 (en) | 2020-11-09 | 2020-11-09 | Composition for preventing or treating cachexia comprising medicinal herb complex extract |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102477343B1 (en) |
WO (1) | WO2022098192A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240109410A (en) | 2023-01-04 | 2024-07-11 | 건국대학교 글로컬산학협력단 | Composition for improving cancer cachexia with Streptonigrin as an active ingredient |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101693828B1 (en) * | 2015-10-30 | 2017-01-09 | 재단법인 통합의료진흥원 | Compostion comprising Yukmijihwangtang extract for treatment of renal cell carcinoma or liver cancer |
KR20190103985A (en) | 2018-02-28 | 2019-09-05 | 중앙대학교 산학협력단 | Composition for Preventing, Improving or Treating Cachexia and Muscle Loss |
KR20200001730A (en) * | 2018-06-28 | 2020-01-07 | 차의과학대학교 산학협력단 | Composition for preventing, improving or treating cachexia comprising Kimchi |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009046391A (en) * | 2005-07-06 | 2009-03-05 | Takehito Kono | Pharmaceutical preparation for improving and treating cachexia and food preparation having cachexia-improving action |
-
2020
- 2020-11-09 KR KR1020200148877A patent/KR102477343B1/en active IP Right Grant
-
2021
- 2021-11-08 WO PCT/KR2021/016150 patent/WO2022098192A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101693828B1 (en) * | 2015-10-30 | 2017-01-09 | 재단법인 통합의료진흥원 | Compostion comprising Yukmijihwangtang extract for treatment of renal cell carcinoma or liver cancer |
KR20190103985A (en) | 2018-02-28 | 2019-09-05 | 중앙대학교 산학협력단 | Composition for Preventing, Improving or Treating Cachexia and Muscle Loss |
KR20200001730A (en) * | 2018-06-28 | 2020-01-07 | 차의과학대학교 산학협력단 | Composition for preventing, improving or treating cachexia comprising Kimchi |
Also Published As
Publication number | Publication date |
---|---|
KR102477343B1 (en) | 2022-12-13 |
WO2022098192A1 (en) | 2022-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102110040B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
JP7132344B2 (en) | Compositions for preventing, ameliorating or treating cachexia and muscle loss | |
KR102477343B1 (en) | Composition for preventing or treating cachexia comprising medicinal herb complex extract | |
KR102203657B1 (en) | A composition comprising the complex extract for antiobesity of women | |
JP6652653B2 (en) | Composition for preventing, ameliorating or treating diseases caused by side effects of anticancer drugs containing ashi extract as an active ingredient | |
KR102449530B1 (en) | Composition for anti-obesity containing extract of Cinnamomum cassia Blume, Atractylodes macrocephala Koidzumi, Pueraria lobata (Willd.) Ohwi, Paeonia lactiflora Pallas and Ephedra sinica Stapf. | |
KR102512655B1 (en) | Composition for preventing or treating cachexia comprising complex extract of Salviae Miltiorrhizae Radix and Rhei Radix et Rhizoma | |
KR101579820B1 (en) | Pharmaceutical compositions for the treatment of cancer metastasis or inhibition of metastasis containing Quassia undulata extracts as active fractions | |
KR20150046916A (en) | Compositions for treating or preventing liver fibrosis or cirrhosis | |
JP6861806B2 (en) | A composition for the prevention, amelioration or treatment of drug-induced renal toxicity containing acetate oleanolate as an active ingredient. | |
WO2022097794A1 (en) | Composition for preventing or treating cachexia, containing complex extract of salviae miltiorrhizae radix and rhei radix et rhizoma | |
KR101552282B1 (en) | Composition for Anti-obesity Containing Dehydrozingerone | |
KR101392345B1 (en) | Pharmaceutical composition for anticancer comprising extract of Lysimachia foenum-graecum as effective component | |
KR102375935B1 (en) | Composition containing piperine for preventing, improving or treating cancer cachexia | |
KR102298385B1 (en) | Composition containing vanillic acid for preventing, improving or treating cancer cachexia | |
KR101181347B1 (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of Dictamnus dasycarpus as active ingredient | |
KR101157214B1 (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of Dipsacus asperoides as active ingredient | |
KR100888068B1 (en) | Compositions for suppressing obesity | |
KR102096345B1 (en) | Composition for preventing, improving or treating vasculitis comprising Curcuma zedoaria extract as effective component | |
KR101932906B1 (en) | Composition for preventing, improving or treating disease caused by side effect of anticancer agent comprising Rumecis Radix extract as effective component | |
CN111356470A (en) | Fraction of analgesic effect of piper nigrum leaf extract | |
KR101578404B1 (en) | Composition for prevention or treatment of cancer containing extract or fraction of Euphorbia L. | |
KR102464897B1 (en) | Herbal Compositions for Prevention, Improvement or Treatment of Benign Prostatic Hyperplasia | |
KR102392292B1 (en) | Composition for preventing or treating cachexia and muscle loss comprising pheniflorin | |
KR20180015029A (en) | Composition for anti-obesity comprising mixed extract of Torilidis Fructus and Curcumae Rhizoma as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |